ReviewDiscover oncology2026
Recent advances in lipid and biomimetic nanocarriers for nucleic acid delivery in glioblastoma.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) remains uniformly lethal due to diffuse invasion, extensive molecular heterogeneity, and a profoundly immunosuppressive microenvironment. Nucleic-acid therapeutics—including antisense oligonucleotides, RNA interference, messenger RNA, and CRISPR-based genome editing—offer programmable control over oncogenic drivers and immune pathways, yet their clinical translation is hindered by rapid nuclease degradation, systemic clearance, restricted blood–brain-barrier transport, inefficient cellular uptake, and endosomal entrapment. Recent progress in nanotechnology has enabled the rational design of nanoparticle platforms that overcome these multilayered biological obstacles. This review summarizes advances (2022–2025) in lipid and biomimetic nanocarriers engineered to enhance nucleic-acid delivery for GBM therapy. For instance, ionizable lipid nanoparticles with pH-responsive chemistry and optimized head-group design achieve efficient cytosolic release with improved biocompatibility, while biomimetic systems, such as cell-membrane-, lipoprotein-, virus-, DNA-, and exosome-mimicking platforms, leverage natural transport and recognition pathways for tumor-specific targeting and immune evasion. Finally, we discuss translational considerations, including GMP-compatible manufacturing, batch consistency, long-term safety and immunogenicity, and advanced model selection, and outline future opportunities in high-throughput lipid discovery, AI-assisted ligand design, hydrogel-mediated spatiotemporal release, and patient-tailored nanotherapies. Collectively, these emerging nanocarriers offer a convergent strategy to navigate physiological barriers and advance precision nucleic-acid therapeutics against glioblastoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.